AstraZeneca Cancer Drug Tagrisso Approved by FDA As First-Line Treatment
April 19 2018 - 2:45AM
Dow Jones News
By Oliver Griffin
AstraZeneca PLC (AZN.LN) said on Thursday that the U.S. Food and
Drug Administration has approved cancer-drug Tagrisso for the
first-line treatment of patients with metastatic non-small cell
lung cancer.
The pharmaceutical company said that the approval by the FDA is
based on results from the phase-three Flaura trial, which were
presented at the European Society of Medical Oncology 2017 Congress
and published in the New England Journal of Medicine.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
April 19, 2018 02:30 ET (06:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
